PF-07220060 (atirmociclib) is undergoing evaluation in numerous clinical trials spanning Early Phase I through Phase IV to assess its safety, efficacy, and pharmacokinetics. Featuring active, recruiting, completed, and terminated protocols, these studies primarily investigate advanced or metastatic ER+ HER2- breast cancer, solid tumors, non-small cell lung cancer, prostate cancer, liposarcoma, and healthy volunteers. The research is sponsored by industry leaders such as Pfizer, Arvinas Estrogen Receptor Inc., and Relay Therapeutics, as well as academic centers including the Dana-Farber Cancer Institute.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07802626 | NOT_YET_RECRUITING | HR Positive/HER-2 Negative Breast Cancer |
SWOG Cancer Research Network |
2026-10-30 | PHASE3 |
| NCT05977036 | RECRUITING | Metastatic Breast Cancer; Unresectable Breast Cancer |
Washington University School of Medicine |
2024-09-25 | |
| NCT07213206 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2025-10-07 | PHASE3 |
| NCT07214532 | RECRUITING | Breast Neoplasms; Carcinoma, Ductal, Breast; Receptors, Estrogen (for ER-positive Requirement) |
Natera, Inc. |
2026-05-08 | |
| NCT07729046 | NOT_YET_RECRUITING | Metastatic Invasive Breast Cancer; Resistant Breast Cancer; ER+, HER2-, Metastatic Breast Cancer |
University of California, San Diego |
2027-07 | PHASE2 |
| NCT06790693 | RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2025-04-09 | PHASE3 |
| NCT07432178 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2026-03-31 | PHASE3 |
| NCT05933395 | RECRUITING | Advanced Breast Cancer |
Dartmouth-Hitchcock Medical Center |
2024-09-23 | PHASE2 |
| NCT06996093 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2025-06-02 | PHASE3 |
| NCT07005557 | NOT_YET_RECRUITING | Breast Cancer; Adjuvant Therapy |
Fudan University |
2025-06-15 | PHASE3 |
| NCT07191717 | RECRUITING | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Invasive Breast Carcinoma; Localized Estrogen Receptor-Positive Breast Carcinoma; Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma |
Jonsson Comprehensive Cancer Center |
2026-05-18 | PHASE2 |
| NCT06380751 | RECRUITING | Advanced Breast Cancer |
AstraZeneca |
2024-08-01 | PHASE3 |
| NCT06120283 | RECRUITING | Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer |
BeOne Medicines |
2023-12-01 | PHASE1 |
| NCT07222267 | RECRUITING | Breast Cancer; Advanced Solid Tumor |
BeOne Medicines |
2025-12-11 | PHASE1 |
| NCT04606446 | RECRUITING | Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer |
Pfizer |
2020-11-16 | PHASE2 |
| NCT07019363 | RECRUITING | Breast Cancer; Adjuvant Therapy |
Fudan University |
2025-06-15 | PHASE3 |
| NCT07527806 | NOT_YET_RECRUITING | Breast Cancer |
Peking University Cancer Hospital & Institute |
2026-05-01 | PHASE2 |
| NCT07174336 | RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-12-22 | PHASE3 |
| NCT07492641 | RECRUITING | HR+/HER2- Breast Cancer |
BeOne Medicines |
2026-05-22 | PHASE3 |
| NCT07340658 | NOT_YET_RECRUITING | Advanced, Metastatic Breast Cancer |
Rovi Pharmaceuticals Laboratories |
2026-08 | PHASE3 |
| NCT06760637 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Pfizer |
2025-01-06 | PHASE3 |
| NCT07419867 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2026-03-01 | PHASE2 |
| NCT04750928 | RECRUITING | Neurofibromatosis 1 |
National Cancer Institute (NCI) |
2021-11-29 | PHASE1; PHASE2 |
| NCT07382687 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2026-02-26 | PHASE3 |
| NCT06997029 | RECRUITING | Advanced Solid Tumor; Advanced Breast Cancer; Advanced Ovarian Cancer |
Bristol-Myers Squibb |
2025-08-01 | PHASE1 |
| NCT07235176 | RECRUITING | Advanced ER+/HER2- Breast Cancer |
Qilu Pharmaceutical Co., Ltd. |
2026-01-16 | PHASE1; PHASE2 |
| NCT06044623 | RECRUITING | Metastatic Breast Cancer; Advanced Breast Cancer; Quality of Life; Toxicity; Older Patients |
Region Örebro County |
2024-04-01 | PHASE3 |
| NCT07766018 | RECRUITING | Breast Cancer |
Stemline Therapeutics, Inc. |
2026-08 | PHASE2 |
| NCT05940493 | RECRUITING | Meningioma |
Nader Sanai |
2025-03-24 | PHASE2 |
| NCT07100106 | RECRUITING | Breast Cancer |
Genentech, Inc. |
2025-10-07 | PHASE1; PHASE2 |
| NCT06377852 | RECRUITING | Metastatic Breast Cancer |
American Society of Clinical Oncology |
2024-10-29 | PHASE3 |
| NCT06680921 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Breast Cancer |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2024-11-14 | PHASE3 |
| NCT06680596 | ENROLLING_BY_INVITATION | Breast Cancer Metastatic; Breast Cancer Stage IV |
UNICANCER |
2025-07-30 | PHASE2 |
| NCT04968964 | RECRUITING | Breast Cancer; Cancer of the Breast |
Washington University School of Medicine |
2022-03-07 | |
| NCT06145308 | RECRUITING | Salivary Gland Carcinoma; Precision Therapy |
Peking Union Medical College |
2023-08-15 | PHASE2 |
| NCT06062498 | RECRUITING | Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer |
Northwestern University |
2023-09-29 | PHASE2 |
| NCT06113809 | RECRUITING | Sarcoma |
John Rieth |
2024-02-01 | PHASE1 |
| NCT05625087 | ACTIVE_NOT_RECRUITING | Breast Cancer Stage IV |
UNICANCER |
2023-10-19 | PHASE2 |
| NCT07037199 | RECRUITING | Advanced Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-08-18 | PHASE2 |
| NCT07666555 | RECRUITING | Breast Cancer |
Fudan University |
2026-06-06 | PHASE2 |
| NCT07198724 | RECRUITING | Metastatic Breast Cancer; HER2 Low Breast Carcinoma; HER2-negative Breast Cancer; Breast Cancer; Breast Cancer Female |
Kristina A. Fanucci |
2025-11-17 | PHASE1; PHASE2 |
| NCT07782840 | NOT_YET_RECRUITING | Breast Cancer |
Hebei Medical University Fourth Hospital |
2026-10-01 | PHASE2 |
| NCT06982521 | RECRUITING | PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer |
Relay Therapeutics, Inc. |
2025-08-26 | PHASE3 |
| NCT07215364 | RECRUITING | Early-stage Breast Cancer |
Spanish Breast Cancer Research Group |
2026-07-02 | |
| NCT07491380 | RECRUITING | Breast Cancer |
Institut Curie |
2026-06-23 | |
| NCT07366112 | RECRUITING | Hormone Receptor-Positive Breast Cancer; High-risk Breast Cancer; Early-Stage Breast Cancer; HER2-negative Breast Cancer; ctDNA Monitoring |
Peking University People's Hospital |
2026-04-20 | PHASE2 |
| NCT07235618 | NOT_YET_RECRUITING | Locally Advanced or Metastatic Breast Cancer |
Sun Yat-sen University |
2026-01-05 | PHASE2 |
| NCT06764186 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Breast Cancer |
AstraZeneca |
2025-01-07 | PHASE3 |
| NCT05601440 | RECRUITING | Breast Cancer |
Canadian Cancer Trials Group |
2023-06-13 | PHASE2 |
| NCT05508906 | RECRUITING | Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Breast Cancer; Locally Advanced Breast Cancer |
Olema Pharmaceuticals, Inc. |
2022-08-31 | PHASE1 |
| NCT07227233 | RECRUITING | Breast Cancer |
University of California, San Diego |
2026-03-31 | PHASE2 |
| NCT04862663 | ACTIVE_NOT_RECRUITING | Locally Advanced (Inoperable) or Metastatic Breast Cancer |
AstraZeneca |
2021-05-10 | PHASE3 |
| NCT07290166 | NOT_YET_RECRUITING | Breast Cancer |
Fudan University |
2025-12-31 | PHASE2 |
| NCT06612814 | ACTIVE_NOT_RECRUITING | Breast Cancer Metastatic |
Zhimin Shao |
2024-09-01 | PHASE3 |
| NCT06650748 | ENROLLING_BY_INVITATION | Breast Cancer; Early-stage Breast Cancer |
Peking University |
2025-05-01 | PHASE2 |
| NCT07137871 | RECRUITING | Breast Cancer Metastatic |
The University of Texas Health Science Center at San Antonio |
2025-10-02 | PHASE1 |
| NCT06382948 | RECRUITING | Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation |
MedSIR |
2024-12-05 | PHASE3 |
| NCT07180160 | RECRUITING | Advanced Breast Cancer |
Wenjin Yin |
2025-09-25 | PHASE2 |
| NCT03439735 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-07-20 | PHASE2 |
| NCT07490236 | RECRUITING | Trilaciclib; CDK4/6-dependent Solid Tumors |
Hebei Medical University Fourth Hospital |
2023-01-01 | PHASE1 |
| NCT05181033 | RECRUITING | Breast Cancer |
National University Hospital, Singapore |
2021-12-27 | PHASE2 |
| NCT07029399 | RECRUITING | HR+ Breast Cancer; Triple Negative Breast Cancer (TNBC); CCNE1 Amplified Advanced Solid Tumors; HR+ HER2- Breast Cancer |
NiKang Therapeutics, Inc. |
2025-03-25 | PHASE1 |
| NCT07258108 | RECRUITING | Breast Cancer |
Sun Yat-sen University |
2025-11-13 | PHASE2 |
| NCT07062965 | RECRUITING | Breast Cancer |
Pfizer |
2025-08-05 | PHASE3 |
| NCT04469764 | RECRUITING | Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma |
Jonsson Comprehensive Cancer Center |
2020-10-16 | PHASE2 |
| NCT05372640 | RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic NUT Carcinoma; Unresectable Breast Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable NUT Carcinoma |
National Cancer Institute (NCI) |
2023-08-10 | PHASE1 |
| NCT07117630 | RECRUITING | Breast Cancer |
Fudan University |
2025-09-25 | PHASE2 |
| NCT04920708 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer |
Royal Marsden NHS Foundation Trust |
2022-12-28 | PHASE2 |
| NCT05113537 | RECRUITING | Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Metastatic Castration-resistant Prostate Carcinoma; Metastatic Castration-resistant Prostate Cancer |
Vadim S Koshkin |
2022-07-08 | PHASE1; PHASE2 |
| NCT05216432 | RECRUITING | PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor |
Relay Therapeutics, Inc. |
2021-12-08 | PHASE1 |
| NCT07446686 | NOT_YET_RECRUITING | Breast Cancer |
Guizhou Provincial People's Hospital |
2026-04-01 | EARLY_PHASE1 |
| NCT06247995 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Novartis Pharmaceuticals |
2024-08-14 | PHASE1; PHASE2 |
| NCT05986071 | NOT_YET_RECRUITING | Breast Cancer |
Institut Paoli-Calmettes |
2024-05-01 | PHASE1; PHASE2 |
| NCT07252726 | RECRUITING | Metastatic Breast Cancer; Metastatic Prostate Cancer |
Ottawa Hospital Research Institute |
2026-02-02 | PHASE4 |
| NCT05691400 | WITHDRAWN | CYP3A4*22 |
University of Michigan Rogel Cancer Center |
2024-03 | PHASE4 |
| NCT06126276 | RECRUITING | Malignant Female Reproductive System Neoplasm; Malignant Solid Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2024-05-07 | PHASE2 |
| NCT06065748 | RECRUITING | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer |
Hoffmann-La Roche |
2023-12-11 | PHASE3 |
| NCT06447623 | RECRUITING | Advanced Breast Cancer; HR+/HER2- Breast Cancer |
Fudan University |
2024-02-01 | PHASE3 |
| NCT07173556 | NOT_YET_RECRUITING | Advanced Breast Cancer |
Qilu Pharmaceutical Co., Ltd. |
2025-09 | PHASE1; PHASE2 |
| NCT05038735 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Novartis Pharmaceuticals |
2021-12-17 | PHASE3 |
| NCT06481956 | ENROLLING_BY_INVITATION | HER2-positive Advanced Breast Cancer |
Zheng Yabing |
2023-10-25 | PHASE2 |
| NCT06207734 | RECRUITING | Breast Cancer |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2024-01-17 | PHASE2 |
| NCT03310879 | RECRUITING | Cancer |
Dana-Farber Cancer Institute |
2017-11-21 | PHASE2 |
| NCT06486883 | RECRUITING | Advanced Breast Cancer; Advanced Breast Carcinoma; Hormone Receptor Positive Breast Carcinoma |
MedSIR |
2025-06-30 | PHASE2 |
| NCT04553133 | ACTIVE_NOT_RECRUITING | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer |
Pfizer |
2020-09-16 | PHASE2 |
| NCT06556862 | NOT_YET_RECRUITING | HR+/HER2- Advanced Breast Cancer |
Beijing 302 Hospital |
2025-10-01 | PHASE2 |
| NCT03065062 | SUSPENDED | Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer |
Dana-Farber Cancer Institute |
2017-02-28 | PHASE1 |
| NCT05870579 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Novartis Pharmaceuticals |
2023-11-13 | PHASE1 |
| NCT07130643 | ACTIVE_NOT_RECRUITING | HR+/HER2- Breast Cancer |
Xinhong Wu, PhD |
2024-12-20 | PHASE2 |
| NCT05860465 | RECRUITING | Locally Advanced or Metastatic Breast Cancer |
Shanghai Pharmaceuticals Holding Co., Ltd |
2023-09-08 | PHASE2; PHASE3 |
| NCT05305924 | RECRUITING | ER-Positive Breast Cancer; HER2-negative Breast Cancer |
The Methodist Hospital Research Institute |
2021-02-25 | PHASE2 |
| NCT04486911 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Shengjing Hospital |
2020-07-27 | PHASE2 |
| NCT07163481 | NOT_YET_RECRUITING | Stage IV (Metastatic) Breast Cancer |
Hunan Cancer Hospital |
2025-10 | PHASE1 |
| NCT05646862 | RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2023-06-07 | PHASE3 |
| NCT05596409 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Stemline Therapeutics, Inc. |
2023-05-19 | PHASE2 |
| NCT06016738 | ACTIVE_NOT_RECRUITING | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma |
Olema Pharmaceuticals, Inc. |
2023-11-16 | PHASE3 |
| NCT03090165 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer |
Kari Wisinski |
2018-05-07 | PHASE1; PHASE2 |
| NCT06929325 | NOT_YET_RECRUITING | HR+/HER2- Advanced/Metastatic Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2025-04 | PHASE3 |
| NCT04557449 | ACTIVE_NOT_RECRUITING | Liposarcoma; Prostate Cancer; Breast Neoplasms; Adenocarcinoma of Lung |
Pfizer |
2020-09-23 | PHASE2 |
| NCT06959979 | RECRUITING | Medulloblastoma, Childhood |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2024-11-25 | EARLY_PHASE1 |
| NCT05262400 | ACTIVE_NOT_RECRUITING | Breast Cancer; Solid Tumors |
Pfizer |
2022-03-14 | PHASE1; PHASE2 |
| NCT04305834 | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
City of Hope Medical Center |
2020-03-25 | PHASE2 |
| NCT05251714 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumor; Breast Cancer |
Treadwell Therapeutics, Inc |
2022-05-27 | PHASE1; PHASE2 |
| NCT05826964 | ACTIVE_NOT_RECRUITING | Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer |
University of Miami |
2023-06-12 | PHASE2 |
| NCT07215078 | COMPLETED | Healthy Volunteer |
Pfizer |
2025-10-08 | PHASE1 |
| NCT05949541 | RECRUITING | Breast Cancer; Advanced Breast Cancer |
Fudan University |
2023-07-26 | PHASE2 |
| NCT05501886 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Celcuity Inc |
2022-12-08 | PHASE3 |
| NCT07214662 | TERMINATED | Breast Cancer |
Genentech, Inc. |
2026-01-13 | PHASE1 |
| NCT04438824 | ACTIVE_NOT_RECRUITING | Well-differentiated/Dedifferentiated Liposarcoma |
Memorial Sloan Kettering Cancer Center |
2020-06-17 | PHASE2 |
| NCT06702618 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2025-02-20 | PHASE2 |
| NCT07409298 | ENROLLING_BY_INVITATION | CDK4/6 Inhibitors; Depression Anxiety Disorder; Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-07-05 | |
| NCT04010357 | COMPLETED | Small-cell Lung Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Extrapulmonary Small Cell Carcinoma |
Case Comprehensive Cancer Center |
2020-01-13 | PHASE2 |
| NCT06570031 | COMPLETED | Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer |
Ono Pharmaceutical Co., Ltd. |
2021-11-09 | PHASE1 |
| NCT05969184 | COMPLETED | Breast Neoplasm Female |
Peking University Cancer Hospital & Institute |
2021-12-12 | PHASE2 |
| NCT06253195 | COMPLETED | Advanced Solid Tumor; Metastatic Solid Tumor; Hormone-receptor-positive Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer |
BeOne Medicines |
2024-04-01 | PHASE1 |
| NCT03285412 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Massachusetts General Hospital |
2017-12-12 | PHASE2 |
| NCT05266105 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Olema Pharmaceuticals, Inc. |
2021-12-10 | PHASE1 |
| NCT06105632 | ACTIVE_NOT_RECRUITING | Advanced or Metastatic Breast Cancer |
Pfizer |
2024-01-09 | PHASE2 |
| NCT06585969 | WITHDRAWN | Metastatic Breast Cancer; ER-positive Breast Cancer; Luminal B; Her2 Enriched; Basal Like |
Danish Breast Cancer Cooperative Group |
2026-01-01 | PHASE3 |
| NCT05536128 | RECRUITING | Advanced Breast Cancer |
Seoul National University Hospital |
2022-12-31 | PHASE2 |
| NCT06750848 | NOT_YET_RECRUITING | Advanced Breast Cancer |
Jundong Wu |
2024-12-20 | PHASE2 |
| NCT05861830 | UNKNOWN | Advanced Breast Cancer |
Peking Union Medical College Hospital |
2023-05-15 | PHASE3 |
| NCT06810492 | NOT_YET_RECRUITING | Breast Cancer Stage III; Breast Cancer Stage II |
Hongmei Zheng, PhD |
2025-04-01 | |
| NCT05586841 | COMPLETED | HR+/HER2- Advanced Breast Cancer |
Beijing 302 Hospital |
2022-10-01 | PHASE1 |
| NCT04819243 | RECRUITING | Premenopausal HR+/HER2- Metastatic Breast Cancer |
Samsung Medical Center |
2021-08-25 | PHASE2 |
| NCT06176534 | RECRUITING | Advanced Breast Cancer; Treatment; HR Low/HER2 Negative |
Henan Cancer Hospital |
2024-01-01 | PHASE2 |
| NCT06363734 | RECRUITING | Non-small Cell Lung Cancer; EGFR Activating Mutation; Cell Cycle Deregulation; EGFR-TKI Resistant Mutation |
Tianjin Medical University Cancer Institute and Hospital |
2024-04-09 | PHASE2 |
| NCT05190094 | RECRUITING | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer |
International Cancer Research Group, United Arab Emirates |
2022-12-20 | PHASE2 |
| NCT06307249 | RECRUITING | Cancer; Solid Tumor; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Targeted Therapy; Chemotherapy; Immunotherapy; Precision Therapy |
Lebanese University |
2023-02-15 | PHASE1 |
| NCT07160738 | COMPLETED | Healthy Adults |
Pfizer |
2025-09-22 | PHASE1 |
| NCT03891784 | ACTIVE_NOT_RECRUITING | Advanced Digestive System Neuroendocrine Neoplasm; Digestive System Neuroendocrine Tumor; Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Neoplasm; Midgut Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Refractory Digestive System Neuroendocrine Neoplasm |
University of Washington |
2019-10-31 | PHASE2 |
| NCT02645149 | COMPLETED | Melanoma |
Melanoma Institute Australia |
2021-11-22 | PHASE2 |
| NCT05759572 | RECRUITING | Breast Cancer Metastatic |
Fudan University |
2023-02-01 | PHASE2 |
| NCT05759546 | RECRUITING | Breast Cancer Metastatic |
Fudan University |
2023-02-01 | PHASE2 |
| NCT06613373 | NOT_YET_RECRUITING | Breast Cancer |
Jiangsu Famous Medical Technology Co., Ltd. |
2024-10-15 | PHASE4 |
| NCT07130097 | COMPLETED | Healthy Participant |
Pfizer |
2025-08-14 | PHASE1 |
| NCT07487129 | COMPLETED | Breast Cancer |
Beni-Suef University |
2024-08-25 | PHASE4 |
| NCT06572800 | COMPLETED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Negative Breast Carcinoma |
Yale University |
2023-09-05 | |
| NCT06206837 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Pfizer |
2024-02-19 | PHASE1; PHASE2 |
| NCT06465368 | COMPLETED | Breast Cancer |
Pfizer |
2024-07-11 | PHASE2 |
| NCT04125277 | ACTIVE_NOT_RECRUITING | Breast Cancer |
The Netherlands Cancer Institute |
2019-12-05 | |
| NCT04964934 | ACTIVE_NOT_RECRUITING | ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2021-06-30 | PHASE3 |
| NCT04650581 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Canadian Cancer Trials Group |
2021-01-27 | PHASE3 |
| NCT06897683 | COMPLETED | Healthy Adults |
Pfizer |
2025-03-21 | PHASE1 |
| NCT05335473 | UNKNOWN | HR Positive HER2 Negative Advanced Breast Cancer |
Henan Cancer Hospital |
2022-05-13 | PHASE1; PHASE2 |
| NCT05865132 | UNKNOWN | Esophagus Squamous Cell Carcinoma |
AIPING ZHOU |
2023-04-06 | PHASE2 |
| NCT05809024 | UNKNOWN | Locally Advanced Breast Cancer; Hormone Receptor Positive，HER2-negative Breast Cancer |
Yongsheng Wang |
2023-03-01 | PHASE4 |
| NCT05806671 | UNKNOWN | Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-05 | PHASE2 |
| NCT06133088 | UNKNOWN | Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed |
Zhejiang Cancer Hospital |
2023-08-01 | PHASE2 |
| NCT06243185 | UNKNOWN | Recurrent Ovarian Carcinoma |
Fengzhi Feng |
2023-11-17 | PHASE2 |
| NCT05303129 | COMPLETED | Breast Cancer; Metastatic Breast Cancer |
Centre Francois Baclesse |
2022-05-27 | |
| NCT05580588 | TERMINATED | Liposarcoma, Dedifferentiated |
Shanghai Pharma Biotherapeutics USA Inc. |
2023-08-31 | PHASE2 |
| NCT03242382 | UNKNOWN | Soft-tissue Sarcoma; Osteosarcoma; Chordoma |
Grupo Espanol de Investigacion en Sarcomas |
2017-03-31 | PHASE2 |
| NCT04594005 | COMPLETED | Tumors |
Yonsei University |
2021-02-25 | PHASE1; PHASE2 |
| NCT03837821 | ACTIVE_NOT_RECRUITING | Bladder Cancer |
Weill Medical College of Cornell University |
2019-02-05 | EARLY_PHASE1 |
| NCT05923411 | COMPLETED | Healthy Participants |
Pfizer |
2023-07-11 | PHASE1 |
| NCT05953350 | RECRUITING | Inhibition of Autophagy Synergizes Anti-tumor Effect |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2023-11-07 | PHASE1; PHASE2 |
| NCT05806047 | UNKNOWN | Hormone Receptor-positive Advanced Breast Cancer |
Fudan University |
2023-05-01 | PHASE2 |
| NCT06267963 | COMPLETED | Healthy Participants |
Pfizer |
2024-01-31 | PHASE1 |
| NCT04251169 | TERMINATED | Metastatic Breast Cancer |
SOLTI Breast Cancer Research Group |
2020-07-21 | PHASE2 |
| NCT05411380 | UNKNOWN | Breast Cancer |
wang shusen |
2022-10-03 | PHASE2 |
| NCT05079360 | WITHDRAWN | Metastatic Breast Cancer |
Veru Inc. |
2023-03-15 | PHASE2 |
| NCT04315233 | TERMINATED | Metastatic Breast Cancer; Recurrent Ovarian Carcinoma |
University of Utah |
2021-05-03 | PHASE1 |
| NCT03024489 | UNKNOWN | Head and Neck Cancer; Locally Advanced |
Mahidol University |
2017-07-19 | PHASE1; PHASE2 |
| NCT05429684 | UNKNOWN | HER2+ Breast Cancer |
First Affiliated Hospital Xi'an Jiaotong University |
2021-01-01 | PHASE3 |
| NCT05169567 | ACTIVE_NOT_RECRUITING | Breast Neoplasm; Neoplasm Metastasis |
Eli Lilly and Company |
2022-03-11 | PHASE3 |
| NCT06206837 | Recruiting | Breast Cancer |
Pfizer|Arvinas Estrogen Receptor Inc. |
2024-02-19 | Phase 1|Phase 2 |
| NCT04869943 | TERMINATED | Metastatic Breast Cancer |
Veru Inc. |
2021-10-12 | PHASE3 |
| NCT05295043 | UNKNOWN | Advanced HR+ HER2 Negative Breast Carcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2022-12-10 | |
| NCT04494958 | COMPLETED | Triple Negative Breast Cancer |
Fundacion Oncosur |
2020-11-18 | PHASE1; PHASE2 |
| NCT03854903 | COMPLETED | Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer |
Georgetown University |
2019-04-01 | PHASE1 |
| NCT04074785 | TERMINATED | GBM; Glioblastoma; Brain Tumor; Brain Tumor, Recurrent |
University of Texas Southwestern Medical Center |
2019-12-13 | EARLY_PHASE1 |
| NCT05670054 | UNKNOWN | Breast Cancer Stage IV |
Mansoura University |
2022-03-01 | PHASE3 |
| NCT05139082 | UNKNOWN | Digestive System Tumors |
Peking University |
2021-11-24 | PHASE1; PHASE2 |
| NCT05808582 | UNKNOWN | Hormone Receptor-positive Advanced Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2023-05-01 | PHASE2 |
| NCT05512780 | UNKNOWN | Solid Tumor |
Hebei Medical University Fourth Hospital |
2022-09-10 | PHASE2 |
| NCT04318223 | UNKNOWN | Metastatic Breast Cancer; Locally Advanced Breast Cancer |
Consorzio Oncotech |
2019-07-16 | PHASE2 |
| NCT04391595 | COMPLETED | Glioblastoma; GBM; Glioma |
Nader Sanai |
2020-07-11 | EARLY_PHASE1 |
| NCT04738292 | TERMINATED | ER-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Cancer |
University of Wisconsin, Madison |
2021-10-05 | PHASE2 |
| NCT03425838 | ACTIVE_NOT_RECRUITING | Breast Neoplasm Female |
Borstkanker Onderzoek Groep |
2017-11-09 | PHASE3 |
| NCT03170206 | COMPLETED | Lung Cancer |
Dana-Farber Cancer Institute |
2017-05-31 | PHASE1 |
| NCT04707196 | COMPLETED | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2021-02-22 | PHASE4 |
| NCT03959891 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Massachusetts General Hospital |
2019-05-30 | PHASE1 |
| NCT03110744 | COMPLETED | Chordoma |
University Hospital Heidelberg |
2017-12-15 | PHASE2 |
| NCT03805399 | UNKNOWN | Triple-negative Breast Cancer |
Fudan University |
2018-10-18 | PHASE1; PHASE2 |
| NCT05371275 | WITHDRAWN | COVID-19 |
biotx.ai GmbH |
2022-04-21 | PHASE2 |
| NCT04733417 | UNKNOWN | Advanced Breast Cancer; Metastatic Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-05-26 | PHASE2 |
| NCT05191914 | UNKNOWN | Breast Cancer |
Liaoning Cancer Hospital & Institute |
2022-02-07 | PHASE4 |
| NCT03555877 | COMPLETED | Breast Cancer Metastatic |
GBG Forschungs GmbH |
2018-03-15 | PHASE2 |
| NCT03237390 | COMPLETED | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm |
Mayo Clinic |
2018-01-04 | PHASE1 |
| NCT02905318 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Canadian Cancer Trials Group |
2017-07-04 | PHASE2 |
| NCT03988114 | WITHDRAWN | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-09-16 | PHASE4 |
| NCT03905889 | TERMINATED | Renal Cell Carcinoma Metastatic |
Brown University |
2019-06-05 | PHASE1 |
| NCT03803761 | WITHDRAWN | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8 |
National Cancer Institute (NCI) |
2019-02-13 | PHASE1; PHASE2 |
| NCT03227328 | COMPLETED | Hormone Receptor Positive Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Negative Breast Cancer |
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
2017-08-02 | PHASE2 |
| NCT06390839 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2017-03-22 | PHASE2 |
| NCT04095390 | UNKNOWN | Metastatic Breast Cancer; HER2-positive Breast Cancer |
Jinming Yu |
2019-09-30 | PHASE2 |
| NCT03965845 | COMPLETED | Solid Tumors; NSCLC; CRC; KRAS Gene Mutation |
Calithera Biosciences, Inc |
2019-06-25 | PHASE1; PHASE2 |
| NCT04615312 | UNKNOWN | Digestive System Tumors |
Henan Cancer Hospital |
2020-11-14 | PHASE1 |
| NCT03778931 | COMPLETED | Breast Cancer |
Stemline Therapeutics, Inc. |
2019-05-10 | PHASE3 |
| NCT04293276 | UNKNOWN | Metastatic Breast Cancer |
Henan Cancer Hospital |
2020-04-01 | PHASE2 |
| NCT03981614 | COMPLETED | Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma |
Academic and Community Cancer Research United |
2019-10-29 | PHASE2 |
| NCT02494921 | COMPLETED | Prostate Cancer |
Rahul Aggarwal |
2015-11-20 | PHASE1; PHASE2 |
| NCT03792256 | COMPLETED | Leukemia, Lymphocytic; Lymphoblastic Lymphoma; T-cell Lymphoma; T-cell Leukemia; Recurrent Disease; Acute Leukemia |
Children's Oncology Group |
2019-04-11 | PHASE1 |
| NCT03238196 | COMPLETED | Metastatic Breast Cancer |
Vanderbilt-Ingram Cancer Center |
2017-08-18 | PHASE1 |
| NCT01723774 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Washington University School of Medicine |
2013-04-10 | PHASE2 |
| NCT03447132 | COMPLETED | Breast Neoplasm Female |
International Cancer Research Group, United Arab Emirates |
2017-12-20 | PHASE3 |
| NCT04162301 | TERMINATED | Advanced Solid Tumor |
CStone Pharmaceuticals |
2019-12-30 | PHASE1 |
| NCT01522989 | UNKNOWN | Advanced Solid Tumor Malignancies |
Georgetown University |
2011-12 | PHASE1 |
| NCT03993964 | UNKNOWN | Metastatic Breast Cancer |
Sun Yat-sen University |
2019-08-15 | PHASE2 |
| NCT03294694 | TERMINATED | Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer; HER2-Negative Breast Cancer; Metastatic Epithelial Ovarian Cancer |
Dana-Farber Cancer Institute |
2017-11-08 | PHASE1 |
| NCT04274933 | TERMINATED | Breast Cancer; Cancer |
AbbVie |
2020-05-21 | PHASE1 |
| NCT02297438 | COMPLETED | Breast Neoplasms |
Pfizer |
2015-03-23 | PHASE3 |
| NCT02657343 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2016-03-09 | PHASE1; PHASE2 |
| NCT01864746 | COMPLETED | Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score |
GBG Forschungs GmbH |
2013-10-30 | PHASE3 |
| NCT04031885 | TERMINATED | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-08-14 | PHASE4 |
| NCT03584009 | TERMINATED | Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-09-06 | PHASE2 |
| NCT03195192 | COMPLETED | Metastatic Breast Cancer |
Side-Out Foundation |
2017-03-09 | |
| NCT03955939 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2019-08-02 | PHASE1 |
| NCT02732119 | COMPLETED | Breast Cancer |
Novartis Pharmaceuticals |
2016-06-14 | PHASE1; PHASE2 |
| NCT02530320 | COMPLETED | Oligodendroglioma; Oligoastrocytoma |
Grupo Español de Investigación en Neurooncología |
2015-10-25 | PHASE2 |
| NCT02345824 | UNKNOWN | Glioblastoma; Glioma |
University of Virginia |
2016-03 | PHASE1 |
| NCT03601598 | UNKNOWN | CRC; HCC; NSCLC |
Harbin Medical University |
2018-07-30 | PHASE1; PHASE2 |
| NCT02763566 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2016-12-05 | PHASE3 |
| NCT03050398 | TERMINATED | Breast Cancer |
Novartis Pharmaceuticals |
2017-06-07 | PHASE3 |
| NCT02255461 | TERMINATED | Childhood Choroid Plexus Tumor; Childhood Ependymoblastoma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor |
Pediatric Brain Tumor Consortium |
2014-12-08 | PHASE1 |
| NCT02501902 | COMPLETED | Metastatic Pancreatic Ductal Adenocarcinoma |
Pfizer |
2015-11-23 | PHASE1 |
| NCT02292550 | COMPLETED | Non-small Cell Lung Cancer |
Novartis Pharmaceuticals |
2015-05-14 | PHASE1 |
| NCT02499146 | COMPLETED | Advanced Breast Cancer |
Pfizer |
2015-09-11 | PHASE1 |
| NCT02607124 | TERMINATED | High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Bithalamic High Grade Glioma |
Children's Hospital Medical Center, Cincinnati |
2016-04 | PHASE1; PHASE2 |
| NCT02187783 | COMPLETED | Tumors With CDK4/6 Pathway Activation |
Novartis Pharmaceuticals |
2014-08-25 | PHASE2 |
| NCT02022982 | COMPLETED | KRAS Mutant Non-Small Cell Lung Cancer; Solid Tumors |
Dana-Farber Cancer Institute |
2014-01 | PHASE1 |
| NCT02107703 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Eli Lilly and Company |
2014-07-22 | PHASE3 |
| NCT02549430 | COMPLETED | Breast Cancer |
Fondazione Sandro Pitigliani |
2012-10 | PHASE2 |
| NCT02246621 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Eli Lilly and Company |
2014-11-06 | PHASE3 |
| NCT02821624 | COMPLETED | Healthy Volunteers |
G1 Therapeutics, Inc. |
2016-05 | PHASE1 |
| NCT02065063 | COMPLETED | Cancer |
GlaxoSmithKline |
2014-04-22 | PHASE1 |
| NCT02414724 | TERMINATED | Lymphoma; Solid Neoplasm |
Roswell Park Cancer Institute |
2015-05 | PHASE1 |
| NCT01684215 | COMPLETED | Neoplasms; Breast Neoplasms |
Pfizer |
2012-10-19 | PHASE2 |
| NCT01740427 | COMPLETED | Breast Neoplasms |
Pfizer |
2013-02-22 | PHASE3 |
| NCT01739309 | COMPLETED | Mantle Cell Lymphoma |
Eli Lilly and Company |
2013-03-20 | PHASE2 |
| NCT02243150 | COMPLETED | Healthy Volunteers |
G1 Therapeutics, Inc. |
2014-09 | PHASE1 |
| NCT01394016 | COMPLETED | Advanced Cancer |
Eli Lilly and Company |
2009-12-07 | PHASE1 |
| NCT01291017 | COMPLETED | Non-small Cell Lung Cancer |
University of Florida |
2011-02 | PHASE2 |
| NCT00721409 | COMPLETED | Breast Cancer |
Pfizer |
2008-09-15 | PHASE2 |
| NCT01709370 | UNKNOWN | ER Positive, HER2 Negative Breast Cancer |
Organisation for Oncology and Translational Research |
2012-02 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
PF-07220060 (CDK4/6-IN-6)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- PF-07220060 (CDK4/6-IN-6) Mechanism of Action: CDK4 Inhibition in Breast Cancer Cell Research
- PF-07220060 (CDK4/6-IN-6) Working Concentration | Cell Culture | Treatment
- PF-07220060 (CDK4/6-IN-6) Solubility in DMSO
- PF-07220060 (CDK4/6-IN-6) Stock Solution
- PF-07220060 (CDK4/6-IN-6) Storage
- PF-07220060 (CDK4/6-IN-6) Stability
- PF-07220060 (CDK4/6-IN-6) Combination Database
- PF-07220060 (CDK4/6-IN-6) Molecular Weight
- PF-07220060 (CDK4/6-IN-6) CAS Number
- PF-07220060 (CDK4/6-IN-6) Chemical Structure (2D and 3D)
- PF-07220060 (CDK4/6-IN-6) Abmole (M45136)? Try a better option.
- PF-07220060 (CDK4/6-IN-6) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.